Infertility
Conditions
Keywords
resveratrol, OHSS, PCOS
Brief summary
Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors
Detailed description
Randomized clinical trial to evaluate the role of resveratrol in preventing ovarian hyperstimulation syndrome by reducing VGEF expression and estradiol production, imporving hemoconcentration and symptomathology of this condition
Interventions
DRUGResveratrol
Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
DRUGPlacebo
Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Sponsors
IVI Madrid
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Number of follicles greater than 12 mm after ovarian stimulation * Number of retrieved oocytes greater than 21
Exclusion criteria
* \>35 years-old * PCOS * Endometriosis * Systemic pathology * Positive serologies for HBV, HBC and HIV * Abnormal karyotype
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum VEGF levels | 1 day | Serum determination of VEGF levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hemoconcentration | 1 day | Volume of red blood cells measured in percentage |
| Serum estradiol levels | 1 day | Serum determination of estradiol levels asessed in picograms per mililiter |
| Ascitis | 1 day | Volume of liquid in Douglas pouch asessed in mililiters |
Countries
Spain
Outcome results
None listed